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Bu Hayee5, Laurent Peyrin-Biroulet6, Andreas Sturm7, Johan Burisch8, Helen Terry9, Luisa Avendano10, 
Seb Tucknott11, Gionata Fiorino12 and Jimmy Limdi13 
Abstract 
Background: Ulcerative colitis (UC) is an inflammatory bowel disease with increasing prevalence worldwide. Current 
treatment strategies place considerable economic and humanistic burdens on patients. The aim of this study was to 
determine the socioeconomic burden of UC in adult patients in European countries in a real-world setting.
Methods: In this retrospective, cross-sectional and observational pan-European study, patients with moderate or 
severe UC were assigned to ARM 1 and patients who had moderate or severe UC but achieved mild or remission sta-
tus 12 months before index date (or clinical consultation date), were assigned to ARM 2. Clinical and medical resource 
use data were collected via electronic case report forms, and data on non-medical and indirect costs, and health-
related quality of life (HRQoL) were collected via patient and public involvement and engagement (PPIE) question-
naires. Per-patient annual total costs per ARM and per country were calculated using the collated resource use in the 
last 12 months (between the start of the documentation period and patient consultation or index date) and country 
specific unit costs. Quality of life  was described by arm and by country.
Results: In the physician-reported eCRF population (n = 2966), the mean annual direct medical cost was €4065 in 
ARM 1 (n = 1835) and €2935 in ARM 2 (n = 1131). In the PPIE population (ARM 1, n = 1001; ARM 2, n = 647), mean 
annual direct cost was €4526 in ARM 1 and €3057 in ARM 2, mean annual direct non-medical cost was €1162 in ARM 
1 and €1002 in ARM 2, mean annual indirect cost was €3098 in ARM 1 and €2309 ARM 2, and mean annual total cost 
was in €8787 in ARM 1 and €6368 in ARM 2. HRQoL scores showed moderate to high burden of UC in both groups.
Conclusions: The cost and HRQoL burden were high in patients in both ARM 1 and ARM 2 indicating unmet needs 
in the UC active population.
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Background
Ulcerative colitis (UC) is a chronic, relapsing and remit-
ting and potentially progressive form of inflammatory 
bowel disease (IBD) of uncertain aetiology, character-
ised by inflammation localised in the mucosa of the 
rectum and colon [1–3]. UC can lead to disease compli-
cations (strictures, bowel perforations and toxic mega-
colon, among others) and extraintestinal manifestations 
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(EIM) in other tissues and organs, including the skin, 
joints, eyes, mouth, liver and lungs [4, 5]. It has an esti-
mated incidence of 1.2–20.3 per 100,000 and a preva-
lence of 7.6–245 per 100,000 [6–10].
Current UC treatment strategies include medica-
tions that aim to induce and maintain clinical remis-
sion, prevent complications (such as hospitalisation, 
surgery, colorectal cancer and EIM) and improve 
health-related quality of life (HRQoL) [4, 11]. Treat-
ment options are usually dictated by severity of dis-
ease and patient preference. In most cases, a step-up 
medication strategy is followed; patients with mild to 
moderate UC symptoms are usually treated with 5-ami-
nosalicylates and corticosteroids, whereas those with 
moderate to severe symptoms are treated with corticos-
teroids, immunosuppressants (such as thiopurines) and 
more advanced targeted therapies such as monoclonal 
antibodies and more recently an orally administered 
JAK inhibitor [2–4]. Despite an expanding armamen-
tarium of therapeutic options, the fluctuating course 
of UC and often unpredictable response to treatment 
implies that patients often experience disease “flares” 
requiring urgent out-patient consultations, hospitali-
sation and surgery for symptoms driven by refractory 
inflammation, complications of disease and hitherto 
under-recognised morbidity from chronic pain and 
psychosomatic issues [12–18].
Exacerbation of UC symptoms has a significant impact 
on health-care utilisation with annual costs of UC care 
reported to be as high as USD 8.1–14.9 billion in the 
USA and Euros 12.5–29.1 billion in Europe. In 2006, the 
mean annual expenditure on healthcare for UC across 
several European countries was estimated to be €1524 
per patient, and the most expensive costs were medical 
and surgical hospitalisations accounting for 45% of the 
total expenditure [19]. Frequent health care utilisation 
and active UC (periods of high intensity of symptoms) 
contributes to work absenteeism and disability, with a 
significant negative impact on HRQoL [19, 20]. Further-
more, fatigue, feeling of isolation and loss of control may 
also negatively impact of quality of life and psychosocial 
well-being of patients and indeed health-care utilisation 
through direct and indirect costs of care [12–15, 17, 18, 
21, 22].
Despite increasing awareness of economic and human-
istic burdens of UC, there is a lack of extensive, up-to-
date and real-world information on the socioeconomic 
burden of active UC.
The overall aim of this study was to provide robust evi-
dence for the identification of the overall socioeconomic 
burden of UC in the EU5 (France, Germany, Italy, Spain, 
United Kingdom [UK]), Denmark, Norway, Poland, 
Romania and Turkey in a real-world setting.
The primary objective of this study was to explore and 
quantify the annual costs of living with active UC from a 
societal perspective (including direct medical, non-med-
ical and indirect costs), and the secondary objective was 
to explore the effect of UC on the HRQoL and produc-
tivity using patient-reported outcomes measurements 
(PROMs) and work-related activity. Patient stratification 




This was a non-interventional, descriptive, retrospec-
tive, cross-sectional, pan-European (EU5, Denmark, 
Norway, Poland, Romania, and Turkey) multi-site study. 
Gastroenterologists were recruited over the study period 
between August 2018–February 2019. Each gastroenter-
ologist provided data from the medical records of their 
patients using standardised questionnaires called elec-
tronic Case Report Forms (eCRFs) for up to 10 eligible 
patients with UC per ARM (20 in total).
Participants
The primary and secondary objectives were analysed by 
disease severity (two ARMs of the study) and country. 
The index date was defined as the date of clinical consul-
tation between the patient and the participating physi-
cian. ARM 1 included patients with moderate or severe 
UC at initiation of the documentation period (12 months 
prior to the index date) as indicated by the Mayo score, 
simple clinical colitis activity index (SCCAI) scores, or 
physician global assessment for UC. ARM 2 included 
patients with moderate or severe UC 24 months prior to 
the index date that achieved mild UC or remission at ini-
tiation of documentation period (12 months prior to the 
index date) as indicated by Mayo score or SCCAI scores 
for UC, or physician global assessment (Fig.  1). Clinical 
remission was defined as a Mayo score of 0–2, PGA of 
0 or SCCAI < 2. Mild UC was defined as a Mayo score of 
3–5, PGA of 1 or SCCAI 2–4. Moderate-severe disease 
was defined by as a Mayo score of 6–10 (moderate) and 
11–12–9 (severe), PGA of 2(moderate), PGA 3(severe) 
or SCCAI > 5. ARM 1 and ARM2 definitions were inde-
pendent of the fact that patient’s severity status could 
fluctuate within the documentation period (as this was 
the case in both arms, due to the fluctuant nature of the 
disease).
Patient inclusion criteria
Patients were included in the study if they were 18 years 
or older at the index date, with UC diagnosis confirmed 
by endoscopy and histology at least 24 months before the 
index date. Patients in ARM 1 had moderate or severe 
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UC at initiation of documentation period (12  months 
prior the index date) as indicated by Mayo or Simple 
Clinical Colitis Activity Index (SCCAI) scores (between 
6 and 10 for moderate patients, and score between 11 
and 12 for severe patients), or by physician global assess-
ment. Patients in ARM 2 had moderate or severe UC that 
achieved mild UC or remission at initiation of documen-
tation period (12  months prior the index date), where 
mild UC was indicated by Mayo or simple clinical coli-
tis activity index (SCCAI) scores (3–5), or by physician 
global assessment and clinical or endoscopic remission 
was indicated by Mayo or SCCAI scores (less than 2) or 
by physician global assessment. Furthermore, patients 
were required to be able to read, understand and sign the 
informed consent form in their local language.
Patient exclusion criteria
Patients were excluded from the study if they were diag-
nosed with Crohn’s Disease and/or IBD unclassified, 
initiated clinical trials/non-interventional study for IBD 
and/or UC treatment 12  months prior the index date, 
could not understand the PPIE questionnaire for issues 
such as language barriers or suffered from a physical or 
mental condition that prevented them from providing 
informed consent.
Variables
Gastroenterologists provided data on each patient, that 
included demographic, clinical (disease history, diag-
nosis, symptoms, complications, etc.) and economic 
information (direct medical resource utilisation: medica-
tions, consultations, hospitalisations and surgical inter-
ventions, tests and procedures used for diagnosis and 
follow-up of disease), via the electronic case report form.
To capture data on HRQoL and other UC-related costs, 
gastroenterologists invited patients to provide informa-
tion via patient and public involvement and engagement 
(PPIE) questionnaires. Data on HRQoL were captured via 
validated tools such as EuroQol-5D-5L (EQ-5D) [23, 24], 
the inflammatory bowel disease disability index (IBD-DI) 
[25] and the IBD control questionnaire (IBD Control Q; 
UK only) [26]. The work productivity and activity impair-
ment (WPAI) [27] questionnaire were used to capture 
productivity losses and impairment in daily life activities 
due to their UC condition.
Data on UC-related costs included direct non-medical 
costs (professional caregiving, alternative therapies, aids 
and home equipment/adaptations, transportation and 
transfer payments—including state benefits or disability 
allowances) and indirect costs (loss of wages and produc-
tivity for patients and their carers due to absenteeism or 
impairment while at work, including early retirement or 
long-term sick leaves due to UC).
Data sources
Clinical health resource use data for each patient was 
captured in the eCRF while direct non-medical and indi-
rect resource use as well HRQoL was captured in the 
PPIE. National unit costs for each resource item were 
sourced from country-specific sources, governmental 
Fig. 1 A representation of the study design, indicating the index date, documentation period and ARMs of study. UC Ulcerative colitis
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documents and national drug pricing databases. A list of 
used sources for each country is available in Additional 
file 1: Table 1.
Statistical analysis
To calculate the cost per ARM, the resource use (RU) and 
unit cost data were collated using homogeneous collec-
tion methods (both CRF and PPIE questionnaires were 
equal across countries, with some country specific differ-
ences to account for differences in health care systems) to 
ensure international comparability, followed by applying 
unit costs to RU data for each country.
Per-patient costs for the 12 months between the start 
of the documentation period and patient consultation or 
index date were calculated by multiplying the quantities 
of the resource used with the national unit price of each 
resource (updated to 2019 prices using inflation indica-
tors via http:// ec. europa. eu/ euros tat/ web/ hicp/ data/ 
datab ase). Applying the unit costs was performed via a 
transparent model design using simple formulae:  Pricei 
×  Quantityi =  Costi; i = 1–n (n = number of cost items). 
Country-specific unit costs were multiplied with the 
resource use quantity to calculate the mean per-patient 
UC-related cost for the 12 months prior to index date. All 
local currency total costs were converted to Euros using 
the official conversion rates as of  30th of august 2019 
(https:// www. oanda. com/ curre ncy/ conve rter/).
Annual Indirect costs were computed by assigning an 
opportunity cost (average salaries of the different coun-
tries were considered) to the disease-related productiv-
ity losses of patients and informal carers. All descriptive 
analyses were performed using Stata 16.
Ethics
The study was approved by the Research Ethics Sub Com-
mittee of the Faculty of Health and Social care within 
the University of Chester (UoC). This study complies 
with UK national requirements and followed the Guide-
lines for Good Pharmacoepidemiology Practices (GPP) 
[28]. An Expert Review Group (ERG) was established to 
ensure the maintenance of quality standards and pro-
vide overall study guidance on behalf of HCD Econom-




The 379 recruited gastroenterologists, primary care and 
internal medicine practitioners completed electronic 
CRFs for 2979 patients. Amongst these, 1657 (55%) 
patients completed the PPIE which was matched to the 
corresponding CRF. Patient response rates for the com-
pletion of PPIEs questionnaires ranged from 16% in the 
United Kingdom to 95% in Romania (see Additional 
file  1: Table  2 for CRF and PPIE response by country), 
which was a reflection of the voluntary nature of the PPIE 
completion and patient willingness to contribute (no 
incentives were given to patients for the completion).
Out of the 2979 CRFs, 1835 were assigned to ARM 1, 
1131 were assigned to ARM 2, and 13 could not be placed 
into an ARM due to lack of disease severity data. Disease 
severity data reflected the fluctuant nature of UC activity, 
with 39% of patients in ARM 1 improving to remission 
or mild status, and 23% of patients in ARM 2 worsening 
to moderate or severe status. Gender, age and body mass 
index (BMI) were largely similar across the two arms 
(Table 1).
Of the 1657 (55%) patients who completed the PPIE 
questionnaire, 1001 were assigned to ARM 1, 647 were 
assigned to ARM  2 and 9 could not be placed into an 
ARM due to lack of severity data.
Table 1 Study population demographics
BMI body mass index, n number, SD standard deviation, UK United Kingdom
ARM 1 ARM 2 Overall
Number of patients (%) 1835 (62) 1131 (38) 2966 (100)
 Male (%) 1023 (56) 615 (53) 1638 (55)
 Female (%) 812 (44) 516 (47) 1328 (45)
Number of severities (12 months 
prior index date)
1835 1131 2966
 Remission (%) – 520 (46) 520 (17)
 Mild (%) – 611 (54) 611 (21)
 Moderate (%) 1457 (79) – 1457 (49)
 Severe (%) 378 (21) – 378 (13)
Number of severities (last 
recorded)
1758 1104 2862
 Remission (%) 134 (8) 300 (27) 434 (15)
 Mild (%) 545 (31) 547 (50) 1092 (38)
 Moderate (%) 885 (50) 209 (19) 1094 (38)
 Severe (%) 194 (11) 48 (4) 242 (8)
Age (n) 1835 1131 2966
 Mean (SD) 46 (15) 48 (15) 47 (15)
BMI (n) 1835 1,131 2966
 Mean (SD) 24.06 (4.2) 24.38 (3.8) 24.18 (4.1)
Country (n) 1835 1131 2966
 Denmark (%) 9 (36) 16 (64) 25 (100)
 France (%) 336 (67) 163 (33) 499 (100)
 Germany (%) 256 (76) 79 (24) 335 (100)
 Italy (%) 348 (62) 217 (38) 565 (100)
 Norway (%) 12 (57) 9 (43) 21 (100)
 Poland (%) 132 (62) 82 (38) 214 (100)
 Spain (%) 344 (58) 250 (42) 594 (100)
 Turkey (%) 42 (35) 78 (65) 120 (100)
 UK (%) 256 (54) 219 (46) 475 (100)
 Romania (%) 100 (85) 18 (15) 118 (100)
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Diagnosis and monitoring
Most patients in ARM 1 and ARM 2 of the eCRF popu-
lation had left-sided colitis (40% and 43%, respectively), 
followed by extensive colitis (26% and 21%, respectively). 
The mean age of diagnosis was 40.5  years across both 
ARMs. Across countries, the mean age at diagnosis var-
ied from 35.8 years in Poland to 45.3 years in Italy.
Comorbidities
In both arms of the eCRF population, 71% of patients 
experienced at least one comorbidity; anaemia was the 
most commonly reported in 34% of patients (with 38% 
and 27% in ARMS 1 and 2 respectively), followed by anxi-
ety and depression in 31% and 16% of patients.
Disease activity
Patients experienced various symptoms at index date and 
12  months prior, where the main five symptoms were 
diarrhoea (62% and 55% at 12  months prior index date, 
and 43% and 30% at index date in ARM 1 and ARM 2 
respectively), rectal bleeding (55% and 44% at 12 months 
prior index date, and 28% and 14% at index date in ARM 
1 and ARM 2 respectively), anaemia (54% and 41% at 
12  months prior index date, and 31% and 19% at index 
date in ARM 1 and ARM 2 respectively), cramping pain 
(47% and 37% at 12  months prior index date, and 32% 
and 20% at index date in ARM 1 and ARM 2 respectively) 
and tiredness/fatigue (38% and 42% at 12  months prior 
index date, and 34% and 36% at index date in ARM 1 and 
ARM 2 respectively).
UC-related complications in patients from ARM 1 
and ARM 2 were reported throughout their life, with 
strictures being the most frequently reported compli-
cations (12% and 9% respectively), followed by fistulas 
(10% and 7% respectively) and perforations (4% and 3% 
respectively).
Despite patients in ARM 2 achieving mild or remission 
status at the initiation of the documentation period, the 
severity of symptoms and complications remained rela-
tively high both at that timepoint but also at index date.
Patients in ARM 1 and ARM 2 experienced anae-
mia (69% and 63%, respectively) and EIMs such as joint 
inflammation (20% in both ARMs) and mouth ulcers 
(13% and 19%, respectively).
Treatment history
To relieve the symptoms of UC, conventional non-bio-
logic and biologic therapies were typically prescribed. 
Non-biologic therapies included mesalazine (62% in 
ARM 1 and 68% in ARM 2), azathioprine (18% in ARM 1 
and 12% in ARM 2) and prednisone (15% in ARM 1 and 
8% in ARM 2), but also less commonly prescribed thera-
pies such as sulfasalazine (9% of all patients), budesonide 
(8%), methotrexate (4%) or tacrolimous (1%). Biologic 
treatments were prescribed to 22% (n = 652) of the study 
population, with infliximab (49% in ARM 1 and 54% in 
ARM 2 respectively) and adalimumab (38% and 35%) 
being the most common, and vedolizumab (10% and 8%), 
golimumab (9% and 6%) and others (not specified, 2% 
and 1%) less commonly prescribed.
Five percent (n = 153) of all the patients had under-
gone at least one surgery for their UC (with 5% and 6% 
of patients of ARM1 and 2 respectively) being colec-
tomy with ileostomy the most frequent procedure (29% 
of these patients) followed by colectomy with ileorectal 
anastomosis (21%), ileal pouch-anal anastomosis (15%), 
proctocolectomy with permanent ileostomy (12%), with 
an additional 25% of patients that received “other” pro-
cedures. An additional 6% (n = 168) of the patients in 
the LUCID study sample were considered “candidates 
for surgery”, with 6% and 4% of patients in ARM 1 and 2 
respectively.
Costs
Table 2 summarises total direct, direct non-medical and 
medical costs in ARMs 1 and 2.
Direct medical costs (via eCRF)
Overall mean direct medical costs were €3949 in the 
PPIE population (n = 1648) and €3634 in the CRF popu-
lation (n = 2966) (Table 2).
In the eCRF population, the mean direct medical cost 
was €4065 in ARM 1 (n = 1835) and €2935 in ARM 
2 (n = 1132). The mean cost was highest in Norway 
(€5373), Germany (€5320), Denmark (€4851) and Italy 
(€4307), and lowest in Turkey (€1299) (Table  3). Bio-
logic treatments incurred the highest mean costs across 
ARMS 1 and 2 and in every country, except for Turkey, 
where costs for consultations were higher than biologic 
treatments.
Direct non‑medical (via PPIE)
Mean annual direct non-medical cost was €1162 in 
ARM 1 and €1002 in ARM 2 (Table 2). The highest over-
all direct non-medical costs across all countries were 
observed in the EU5 countries and Poland; the largest 
was reported in patients from Italy (€1787) (Table  3). 
Professional caregiver costs were the most expensive 
items across both ARMS and most countries, followed by 
support services (e.g., nutritionists and physiotherapists) 
and transfer payments from the government.
Indirect costs (via PPIE)
Mean annual indirect cost was €3098 in ARM 1 and 
€2309 ARM 2 (Table 2). Most indirect costs were attrib-
uted to long term sick leaves and early retirements from 
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patients, with close to 50% of total indirect costs, whereas 
time from informal caregivers and time off work in the 
last 12  months had similar proportions. At the country 
level, France had the highest recorded mean indirect cost 
(€4,334) followed by Spain (€3061), the UK (€3045) and 
Italy (€2876) (Table 3).
Calculating HRQoL via validated PROMs
Tables  4, 5 and 6 summarise PPIE population patient 
responses to the EQ-5D-5L, IBD-DI and WPAI 
questionnaires.
EQ‑5D‑5L, IBD‑DI and WPAI
The EQ5D-5L questionnaire was completed by 994 in 
ARM 1 and 637 patients in ARM 2. The overall mean 
total EQ-5D index score was 0.83, with 0.81 and 0.86 in 
the ARMs 1 and 2, respectively. The EQ-5D scores var-
ied between the countries included in this study. In ARM 
1, the highest EQ-5D score was observed in Norway 
(0.91) and the lowest in France (0.8). In ARM 2, the high-
est EQ-5D score was observed in Denmark (0.95) and 
the lowest in Romania (0.8) (Table  5). EQ-5D review of 
dimensions revealed a greater impact in the pain/discom-
fort and anxiety depression domains across both arms, 
whereas it showed a limited impact on mobility, self-care 
and usual activities.
The IBD-DI questionnaire was completed by 1000 
patients in ARM 1 and 647 patients in ARM 2. The over-
all mean total IBD–DI score was 27.3, with 30.6 and 
22.3 in ARMs 1 and 2, respectively (Table 4). The high-
est IBD–DI scores in ARM 1 and ARM 2 were in Italy 
(35.6) and Romania (30.6) respectively, whereas the low-
est scores were in Denmark (19 and 9.6, respectively; 
Table 5).
In the PPIE population, 1001 patients ARM 1 and 647 
patients in ARM 2, completed the work productivity and 
activity impairment (WPAI) questionnaire. Work pro-
ductivity loss was the most affected dimension in both 
Table 2 Total direct medical, direct non-medical and indirect costs by ARM
CRFs case record forms, n number PPIEs patient public involvement engagement, SD standard deviation, Pop population
ARM 1 ARM 2 Overall
CRF population, direct medical cost (n) 1835 1131 2966
 Mean (SD) €4065 (10,182) €2935 (7327) €3634 (9214)
 Biologic Tx €2646 (9285) €1829 (6979) €2334 (8488)
 Procedure/Test €174 (215) €174 (204) €174 (211)
 Non-Biologic Tx €376 (1692) €358 (1437) €369 (1599)
 Surgery €87 (638) €96 (615) €90 (629)
 Consultation €492 (859) €402 (535) €458 (753)
 Hospitalisation €289 (1885) €76 (571) €208 (1527)
PPIE population, (n) 1001 647 1648
Direct medical cost, mean (SD) €426 (10,849) €3057 (7790) €3949 (9787)
 Biologic Tx €3007 (9718) €1964 (7468) €2,597 (8915)
 Procedure/Test €171 (193) €181 (177) €175 (187)
 Non-Biologic Tx €396 (1780) €394 (1426) €395 (1650)
 Surgery €74 (471) €63 (403) €70 (445)
 Consultation €527 (1064) €387 (535) €472 (897)
 Hospitalisation €352 (2238) €67 (649) €240 (1796)
Direct non‑medical cost, mean (SD) €1162 (3761) €1002 (3276) €1099 (3578)
 Professional caregiver €493 (3326) €437 (2581) €471 (3054)
 Home alteration €48 (187) €41 (194) €45 (190)
 OTC medication €80 (153) €64 (124) €74 (142)
 Transport €96 (196) €116 (584) €104 (397)
 Transfer payments €218 (1134) €129 (890) €183 (1045)
 Alternative therapy €227 (737) €216 (866) €222 (790)
Indirect cost, mean (SD) €3098 (9091) €2309 (7379) €2789 (8467)
 Non-professional caregiver €767 (3689) €642 (2791) €718 (3365)
 Retire/stop working €1456 (6724) €1419 (6330) €1441 (6570)
 Time off work in the last 12 months €875 (3311) €249 (1112) €630 (2689)




































Table 3 Total direct medical, direct non-medical and indirect costs by country


























31 500 335 565 22 214 595 120 479 118 2979
 Mean (SD) €4851 (12,911) €3357 (5841) €5320 (13,311) €4307 (11,414) €5373 (13,269) €3762 (8740) €4084 (9418) €1299 (7700) €2024 (4505) €2792 (6797) €3643 (9217)
PPIE popula‑
tion, (n)





€5362 (14,754) €3303 (5777) €4802 (13,142) €4500 (12,100) €2404 (4822) €2787 (6380) €4551 (10,189) €2478 
(11,057)









€638 (2360) €4334 (13,336) €2210 (7252) €2876 (6878) €0 (0) €1964 (5055) €3061 (7726) €80 (414) €3045 (8001) €820 (2202) €2812 (8500)
 Total cost, 
mean (SD)




€4152 (7214) €7854 (14515)
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arms, with mean scores of 0.28 and 0.20, respectively 
(Table 4).
Discussion
Despite the growing number of cost-effectiveness stud-
ies of new pharmacological interventions (biologics), 
no previous studies have focused on the overall burden 
of UC, including costs beyond medical management. To 
our knowledge, this is the first study to adopt a societal 
perspective at the pan-European level. Compared with 
indirect costs, the direct medical cost was higher across 
both arms of the study. Indirect costs, however, were sub-
stantial, highlighting the need for a holistic perspective 
to have a better appreciation on the true cost of care for 
patients with UC.
Over the years, biologic treatment is the main driver 
for direct medical costs [15, 17, 18, 21, 22]. It is likely 
that their proportion in total costs is smaller than what 
is stated in this study due to the practical difficulties with 
capturing real transaction prices and also because this 
study did not capture the proportion of biosimilar use 
vs cost of original biologic. Accounting for competitive 
processes such as regional or hospital tenders, non-trans-
parent price discounts etc. poses real practical challenges 
and whilst desirable, remain unrealistic and must be 
acknowledged as a possible limitation of our work.
Patients in ARM 1 reported a higher impairment in 
both HRQoL and work productivity and activity than 
patients in ARM 2, suggesting a direct relationship 
between UC activity and morbidity from disease, how-
ever a formal statistical comparison was not the objec-
tive of this exploratory study. Patients with active UC 
have been reported to have higher health care related 
costs from the direct cost of diagnostic tests, medication, 
hospitalisation and surgery but also from indirect costs 
such as reduced employment, effect on work-productiv-
ity and opportunities for unpaid activities [29–31]. The 
EQ-5D-5L show a relatively small impact of the disease 
in patients, with high scores per ARM, which might be 
explained by low sensitivity of the measuring instru-
ment, the fluctuating nature of the disease (many patients 
changed to different severity status in the 12  months 
documentation period, resulting in mixed results) and 
recall period of 1 day “your health today”. Also, the real-
istic possibility of corticosteroid therapy in these patients 
in controlling symptoms but not necessarily achieving 
meaningful remission may mask true disease activity.
The relatively small differences observed in total 
costs results in both arms suggest that there are signifi-
cant unmet needs and associated costs in patients even 
when they achieve mild and remission status (definition 
of ARM 2 in this study). Again, the fluctuant nature of 
disease severity (39% of patients in ARM 1 improving to 
mild or remission and 23% of those in ARM 2 worsening 
to moderate or severe) may partly explain these results. 
The ARM- and country-specific IBD-DI scores imply 
an impact on Quality of Life, but also suggest that the 
EQ-5D might not be a sensitive enough tool in a disease 
with a fluctuating nature such as UC. The mean IBD con-
trol score, which was only captured in UK patients, was 
7.3 in ARM 2 and 7.1 in ARM 1. Therefore, it is recom-
mended to carry out further detailed analysis of the data, 
focusing on the relationship between changing severity 
and clinical and economic outcomes.
The proportion of patients with strictures as a compli-
cation of their UC was higher than expected at 12% and 
9% for ARM 1 and ARM 2 respectively. Previous stud-
ies have reported a prevalence of 1.5%, 3.2% and 6.5% 
respectively [32–34]. It is possible that this unexpectedly 
large proportion of UC patients with strictures is indica-
tive of long standing aggressive or sub-optimally con-
trolled disease and is concerning. Alternatively, it is also 
possible that there has been a degree of misclassification 
of patients with Crohn’s disease, suggested by the stric-
tures but also by the high prevalence of fistulas in this 
Table 4 Patient-reported IBD-DI, EQ-5D and WPAI scores in the 
PPIE population by ARM
EQ-5D EuroQol‑5 dimension, IBD-DI inflammatory bowel disease disability index, 
IQR interquartile range, n number, PPIE patient and public involvement and 
engagement, SD standard deviation, UK United Kingdom, VAS visual analogue 
scale, WPAI work productivity and activity impairment
ARM 1 ARM 2 Overall
EQ‑5D total score (n) 994 637 1631
 Mean (SD) 0.81 (0.17) 0.86 (0.16) 0.83 (0.17)
 Median (IQR) 0.84 (0.21) 0.90 (0.19) 0.86 (0.18)
EQ‑5D VAS score (n) 1001 647 1648
 Mean (SD) 71.2 (18.3) 76.6 (16.2) 73.3 (17.7)
 Median (IQR) 75 (25) 80 (20) 75 (25.5)
IBD‑DI score (n) 1000 647 1647
 Mean (SD) 30.6 (18.9) 22.3 (16.6) 27.3 (18.5)
IBD control score, UK only (n) 29 42 71
 Mean (SD) 7.1 (3.7) 7.3 (2.1) 7.2 (2.9)
WPAI Scores in Total PPIE popula‑
tion
1001 647 1648
Work time missed (absenteeism; 
%)
517 (52) 324 (50) 841 (51)
 Mean (SD) 0.11 (0.25) 0.06 (0.19) 0.09 (0.23)
Impairment (presenteeism; n) 484 (48) 315 (49) 799 (48)
 Mean (SD) 0.24 (0.21) 0.18 (0.19) 0.22 (0.20)
Work productivity loss (n) 484 (48) 315 (49) 799 (48)
 Mean (SD) 0.28 (0.24) 0.20 (0.21) 0.25 (0.23)
Activity Impairment (n) 602 (60) 368 (57) 970 (59)




































Table 5 Patient-reported IBD-DI and EQ-5D scores in the PPIE population by country and ARM
EQ-5D EuroQol‑5 dimension, IBD-DI inflammatory bowel disease disability index, IQR interquartile range, n number, SD standard deviation, VAS visual analogue scale, WPAI work productivity and activity impairment
Denmark (n = 31) France (n = 500) Germany (n = 335) Italy (n = 565) Norway (n = 22) Poland (n = 214)
ARM 1 ARM 2 ARM 1 ARM 2 ARM 1 ARM 2 ARM 1 ARM 2 ARM 1 ARM 2 ARM 1 ARM 2
EQ‑5D total score 
(n)
6 11 216 116 124 42 199 116 4 2 85 41




0.83 (0.12) 0.91 (0.1) 0.91 (0.04) 0.93 (0.1) 0.84 (0.2) 0.86 (0.15)
























IBD‑DI score (n) 6 11 218 116 124 43 199 119 4 2 87 41
 Mean (SD) 18.98 (21.3) 9.58 (10.96) 26.87 (18.41) 17.32 (15.81) 29.73 (18.47) 22.58 (15.48) 35.61 (19.29) 26.92 (18.18) 22.68 (10.87) 18.75 (11.36) 23.64 (20.4) 23.47 (15.52)
Spain (n = 595) Turkey (n = 120) United Kingdom (n = 479) Romania (n = 118) Overall (n = 2979)
ARM 1 ARM 2 ARM 1 ARM 2 ARM 1 ARM 2 ARM 1 ARM 2 ARM 1 ARM 2
EQ‑5D total score (n) 224 201 12 45 31 46 93 17 994 637
 Mean (SD) 0.8 (0.17) 0.86 (0.16) 0.89 (0.11) 0.92 (0.09) 0.85 (0.13) 0.9 (0.11) 0.84 (0.16) 0.8 (0.15) 0.81 (0.17) 0.86 (0.16)




















IBD‑DI score (n) 225 206 12 45 31 47 95 17 1001 647




































Table 6 Patient-reported WPAI scores in the PPIE population by country


























14 157 123 168 3 73 188 17 30 74 847




14 150 117 155 3 66 180 17 30 73 805
 Mean (SD) 0.06 (0.06) 0.21 (0.21) 0.22 (0.16) 0.26 (0.22) 0.1 (0.17) 0.23 (0.22) 0.2 (0.2) 0.14 (0.14) 0.29 (0.27) 0.18 (0.17) 0.22 (0.2)
Work produc‑
tivity loss (n)
14 150 117 155 3 66 180 17 30 73 805




16 198 127 187 4 83 226 29 34 74 978
 Mean (SD) 0.06 (0.09) 0.27 (0.25) 0.26 (0.21) 0.28 (0.22) 0.08 (0.15) 0.25 (0.26) 0.21 (0.22) 0.14 (0.19) 0.28 (0.25) 0.17 (0.18) 0.24 (0.23)
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population (10% and 7% in arms 1 and 2 respectively). 
Nevertheless, it is important that the study is reflective of 
everyday practice, where categorisation of patients may 
not be straightforward.
Also, the proportion of patients experiencing diar-
rhoea, rectal bleeding, anaemia, crampy abdominal pain 
and fatigue in ARM 2 was not far behind that in ARM 1, 
which could explain to some degree the relatively small 
differences in costs in the two groups. This raises several 
questions with respect to quality and perception of dis-
ease control. It is possible that sub-optimally controlled 
disease and the naturally fluctuant disease course therein 
triggered these symptoms and emphasises the need to 
treat beyond symptoms aiming for endoscopic remission 
where possible to mitigate gut injury and active symp-
toms stemming from sub-optimal disease control [35, 
36]. The impact of the wider adoption of a treat to target 
strategy on optimal disease control and its implications 
to quality of life represent an area of urgent and unmet 
research need.
There is increasing awareness that ulcerative colitis is 
a progressive disease and that long standing disease may 
lead to complications such as stricturing, dysmotility, 
anorectal dysfunction and altered colonic permeability 
which may also be a driver of symptoms such as diar-
rhoea and incontinence [16, 37, 38].
This study had limitations that must be considered 
before reaching an overall consensus. Some countries 
(e.g., Spain) have a much larger population sample than 
others (e.g., Norway), which could increase the uncer-
tainty of the final costs in the latter. EQ-5D results sug-
gest a low sensitivity to changes in disease severity. 
Additionally, the short recall period "your health today" 
of this tool, coupled with the fluctuant nature of UC, 
challenge the interpretation of these data. Despite phy-
sicians having no choice in selection of participants, 
the next ten patients seen in clinical consultation are 
selected, selection bias may still be present. Mild patients 
are more likely to be seen in clinical consultation as the 
disease is often newly diagnosed. Severe patients are also 
more likely to be seen in clinical consultation as they 
need the most attention. This can lead to selection bias 
against remission and/or moderate patients.
The higher costs in the PPIE population compared with 
those in the CRF population suggests that the respond-
ing patients and the main LUCID population should not 
be compared directly; this difference would partly explain 
the EQ5D results being higher than expected and sug-
gesting that there might be a difference (bias) between 
patients who respond versus those who do not.
Conclusion
The initial results of this study suggest that there is a 
significant cost associated with UC management in 
both arms, with a relatively high cost even for patients 
that reach remission or mild status. Despite the rela-
tively high EQ-5D scores in the UC population, analysis 
of IBD-DI, work productivity and indirect costs sug-
gest an unmet need in the UC population, especially 
in ARM 1 of the study. Furthermore, the high level of 
symptoms, disease complications, comorbidities and 
EIMs further reinforce this unmet need. This study 
provided insight into the per-patient costs within 10 
participating European countries with markedly differ-
ent healthcare provisions and settings, thereby aiding 
stakeholders with the opportunity to understand the 
economic landscape of the condition better. The out-
comes of the LUCID study will help develop relevant 
public health actions and policies and help improve UC 
clinical guidelines.
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